Columbus Macro LLC Raises Holdings in Stryker Co. (NYSE:SYK)

Columbus Macro LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 474.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,494 shares of the medical technology company’s stock after buying an additional 11,970 shares during the period. Columbus Macro LLC’s holdings in Stryker were worth $5,219,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Czech National Bank increased its stake in Stryker by 8.1% during the 3rd quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after purchasing an additional 5,235 shares in the last quarter. GAMMA Investing LLC raised its stake in Stryker by 38.7% in the 3rd quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock worth $1,048,000 after acquiring an additional 810 shares during the last quarter. Diversified Trust Co grew its stake in Stryker by 5.8% during the 3rd quarter. Diversified Trust Co now owns 14,581 shares of the medical technology company’s stock valued at $5,268,000 after purchasing an additional 800 shares during the last quarter. Consilio Wealth Advisors LLC acquired a new position in shares of Stryker in the third quarter valued at about $210,000. Finally, Miracle Mile Advisors LLC raised its stake in shares of Stryker by 569.2% in the third quarter. Miracle Mile Advisors LLC now owns 5,983 shares of the medical technology company’s stock worth $2,161,000 after purchasing an additional 5,089 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK stock opened at $390.97 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market cap of $149.05 billion, a P/E ratio of 50.38, a P/E/G ratio of 2.78 and a beta of 0.96. The business’s 50 day moving average price is $376.68 and its 200-day moving average price is $363.22.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a $0.84 dividend. The ex-dividend date was Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of analysts have recently commented on SYK shares. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Barclays boosted their price objective on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. UBS Group boosted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Insiders Place Their Bets

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.